GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merus Labs International Inc (NAS:MSLI) » Definitions » Price-to-Owner-Earnings

Merus Labs International (Merus Labs International) Price-to-Owner-Earnings : (As of Apr. 26, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Merus Labs International Price-to-Owner-Earnings?

As of today (2024-04-26), Merus Labs International's share price is $1.30. Merus Labs International does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Merus Labs International's Price-to-Owner-Earnings or its related term are showing as below:


MSLI's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 27.58
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-26), Merus Labs International's share price is $1.30. Merus Labs International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2017 was $-0.08. Therefore, Merus Labs International's PE Ratio for today is At Loss.

As of today (2024-04-26), Merus Labs International's share price is $1.30. Merus Labs International's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.08. Therefore, Merus Labs International's PE Ratio without NRI for today is At Loss.


Merus Labs International Price-to-Owner-Earnings Historical Data

The historical data trend for Merus Labs International's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merus Labs International Price-to-Owner-Earnings Chart

Merus Labs International Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 14.33 10.30

Merus Labs International Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.33 25.60 10.30 12.43 15.50

Competitive Comparison of Merus Labs International's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Merus Labs International's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merus Labs International's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merus Labs International's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Merus Labs International's Price-to-Owner-Earnings falls into.



Merus Labs International Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Merus Labs International's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.30/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merus Labs International  (NAS:MSLI) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Merus Labs International Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Merus Labs International's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Merus Labs International (Merus Labs International) Business Description

Traded in Other Exchanges
N/A
Address
Merus Labs International Inc was incorporated on October 1, 2012 in British Columbia. The Company is a specialty pharmaceutical company. It acquires prescription medicines in various categories which include on patent but at maturity stage of product life cycle; branded generics; under promoted products; Niche market pharmaceuticals; and products with annual sales below critical threshold for large pharma. The Company competes with multinational pharmaceutical development corporations to small, single product companies that may limit their activities to a particular therapeutic area or region or territory.

Merus Labs International (Merus Labs International) Headlines